Adlai Nortye (ANL) Investor Presentation summary

Mechanism of action and innovation

• AN8025 is a tri-specific antibody fusion protein combining aPD-L1, CD86 variant, and LAG3 variant to enhance immune response against tumors.

• LAG3 component stimulates differentiation and maturation of antigen-presenting cells (APCs), while CD86 and aPD-L1 synergistically amplify tumor-specific T cell responses.

• AN8025 blocks both PD-L1 and CTLA-4 pathways, promoting T cell reactivation and efficient tumor cell killing.

• Demonstrates superior T cell activation in a PD-L1-dependent manner compared to existing therapies.

Preclinical efficacy and safety

• AN8025 shows potent anti-tumor activity in vivo, reducing tumor volume in preclinical models.

• Enhances both the quantity and quality of APCs, leading to improved immune function.

• Exhibits dose-dependent exposure and favorable pharmacokinetics in non-human primates.

• Mild cytokine release observed only at high doses, indicating a favorable safety profile.

Development plans and partnerships

• IND submission for AN8025 is planned for mid-2025.

• Ongoing efforts to secure partnerships with pharmaceutical and biotech companies.